Back to Search Start Over

Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing.

Authors :
van Zyl-Smit RN
Pai M
Peprah K
Meldau R
Kieck J
Juritz J
Badri M
Zumla A
Sechi LA
Bateman ED
Dheda K
Source :
American journal of respiratory and critical care medicine [Am J Respir Crit Care Med] 2009 Jul 01; Vol. 180 (1), pp. 49-58. Date of Electronic Publication: 2009 Apr 02.
Publication Year :
2009

Abstract

Rationale: The optimal strategy for the diagnosis of latent tuberculosis infection is controversial. Adoption of a two-step strategy (tuberculin skin test [TST] followed by an IFN-gamma release assay [IGRA], compared with an IGRA alone), may be limited by TST-mediated boosting of subsequent IGRA responses. Assessment of within-subject IGRA variability will aid in establishing thresholds for conversions and reversions, and interpretation of serial testing results.<br />Objectives: To determine short-term IGRA variability and the impact of TST on subsequent IGRA results.<br />Methods: Within-subject variability and TST-mediated boosting of IGRA responses were evaluated in 26 South African participants with varying exposure risk. IGRAs (T-SPOT.TB, QuantiFERON-TB Gold In-Tube [QuantiFERON-TB-GIT], PPD, and heparin-binding hemagglutinin) were repeated four times over 21 days pre-TST, and on Days 3, 7, 28, and 84 post-TST administration.<br />Measurements and Main Results: All participants showed within-subject IGRA variability. Changes of +/-3 spots (T-SPOT.TB) or +/-80% from the mean IFN-gamma response (QuantiFERON-TB-GIT) over 3 weeks explained 95% of the variability. Spontaneous conversions/reversions occurred in 7 of 26 subjects (27%) (6 for T-SPOT.TB and 1 for QuantiFERON-TB-GIT [P = 0.049]) during the within-patient variability studies (pre-TST). After the TST eight subjects (33%) boosted above the defined baseline variability. By Day 7 post-TST, but not Day 3, 2 (12.5%) initially IGRA-negative test subjects converted. By contrast, boosting of PPD and heparin-binding hemagglutinin occurred by Day 3 post-TST.<br />Conclusions: When using a two-step screening strategy it appears safe to perform a QuantiFERON-TB-GIT or T-SPOT.TB IGRA within 3 days of performing the TST. A 3-spot or 80% IFN-gamma response variation, on either side of baseline values, explains 95% of the short-term variability and may be useful for interpreting conversions and reversions, and values close to the cut-point.

Details

Language :
English
ISSN :
1535-4970
Volume :
180
Issue :
1
Database :
MEDLINE
Journal :
American journal of respiratory and critical care medicine
Publication Type :
Academic Journal
Accession number :
19342414
Full Text :
https://doi.org/10.1164/rccm.200811-1704OC